<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1204</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2019-19-2-55-64</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">ASSESSMENT OF THE TOXICOLOGICAL PROPERTIES OF DOCETAXEL LOADED FOLATE-MODIFIED POLYMER PARTICLES IN VIVO</article-title><trans-title-group xml:lang="ru"><trans-title>ОЦЕНКА ТОКСИКОЛОГИЧЕСКИХ СВОЙСТВ ДОЦЕТАКСЕЛА В СОСТАВЕ ФОЛАТМОДИФИЦИРОВАННЫХ ПОЛИМЕРНЫХ ЧАСТИЦ В ЭКСПЕРИМЕНТЕ IN VIVO</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7985-9314</contrib-id><name-alternatives><name xml:lang="en"><surname>Krasheninnikova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Крашенинникова</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Akademika Kurchatova ploshchad’, Moscow 123182</p><p>8 Baltiyskaya St., Moscow 125315</p></bio><bio xml:lang="ru"><p>Анна Андреевна Крашенинникова</p><p>123182 Москва, пл. Академика Курчатова, 1</p><p>125315 Москва, ул. Балтийская, 8</p></bio><email>a.a.krasheninnikova@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9550-4206</contrib-id><name-alternatives><name xml:lang="en"><surname>Zavarzina</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Заварзина</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Akademika Kurchatova ploshchad’, Moscow 123182</p></bio><bio xml:lang="ru"><p>123182 Москва, пл. Академика Курчатова, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7421-6961</contrib-id><name-alternatives><name xml:lang="en"><surname>Panova</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Панова</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Akademika Kurchatova ploshchad’, Moscow 123182</p></bio><bio xml:lang="ru"><p>123182 Москва, пл. Академика Курчатова, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7163-4527</contrib-id><name-alternatives><name xml:lang="en"><surname>Gukasova</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Гукасова</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Akademika Kurchatova ploshchad’, Moscow 123182</p></bio><bio xml:lang="ru"><p>123182 Москва, пл. Академика Курчатова, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6290-5142</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuznetsov</surname><given-names>S. L.</given-names></name><name xml:lang="ru"><surname>Кузнецов</surname><given-names>С. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Akademika Kurchatova ploshchad’, Moscow 123182</p></bio><bio xml:lang="ru"><p>123182 Москва, пл. Академика Курчатова, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9461-4219</contrib-id><name-alternatives><name xml:lang="en"><surname>Tubasheva</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Тубашева</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Akademika Kurchatova ploshchad’, Moscow 123182</p></bio><bio xml:lang="ru"><p>123182 Москва, пл. Академика Курчатова, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5744-7060</contrib-id><name-alternatives><name xml:lang="en"><surname>Balabanyan</surname><given-names>V. Yu.</given-names></name><name xml:lang="ru"><surname>Балабаньян</surname><given-names>В. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Leninskie Gory, Moscow 119991</p></bio><bio xml:lang="ru"><p>119991 Москва, Ленинские горы, 1</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2803-0426</contrib-id><name-alternatives><name xml:lang="en"><surname>Poltavets</surname><given-names>Yu. I.</given-names></name><name xml:lang="ru"><surname>Полтавец</surname><given-names>Ю. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>1 Akademika Kurchatova ploshchad’, Moscow 123182</p></bio><bio xml:lang="ru"><p>123182 Москва, пл. Академика Курчатова, 1</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Research Center “Kurchatov Institute”</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный исследовательский центр «Курчатовский институт»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of General Pathology and Pathophysiology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт общей патологии и патофизиологии»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">M.V. Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-06-18" publication-format="electronic"><day>18</day><month>06</month><year>2020</year></pub-date><volume>19</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>55</fpage><lpage>64</lpage><history><date date-type="received" iso-8601-date="2020-06-18"><day>18</day><month>06</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-06-18"><day>18</day><month>06</month><year>2020</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1204">https://bioterapevt.abvpress.ru/jour/article/view/1204</self-uri><abstract xml:lang="en"><p><bold><italic>Introduction </italic></bold><italic>One of the perspective approaches to the development of anticancer chemotherapy drugs is the use of submicron vectorizeddelivery systems that increase the selectivity of action and reduce the toxic side effects of chemotherapy. A delivery system of docetaxel(DOC) loaded poly(lactide-co-glycolide) (PLGA) particles modified with folic acid dodecylamide (FAD) was developed (PLGA-DOC-FAD). <bold>The aim </bold>of the research was a comparative toxicological study of DOC-loaded particles and standard docetaxel solution form in acuteand subchronic experiments in mice after intravenous administration. <bold>Materials and methods </bold>The research was conducted in female C57BL/6 mice. During the study of acute toxicity, drugs were administeredin the following dose range: 20, 60, 90, 120, 160 mg/kg. Over 30 days, mortality and body weight were evaluated, pathomorphologicalstudies were performed. The study of toxicity in conditions of subchronic administration of medicine was conducted using three timesdaily administration in single doses of 11 and 22 mg/kg. Subchronic toxicity of the drugs was studied with three times daily administrationin single doses of 11 and 22 mg/kg. The necessary studies were performed within 30 days. <bold>Results </bold>With a single injection of PLGA-DOC-FAD in doses of 20, 60, 90 mg/kg, the death of animals wasn’t observed; at doses of 120 and160 mg/kg, the death of animals was detected in 1–4 days. In the case of administration of the DOC substance, the death of animalsoccurred within a day after the administration of doses of 60, 90, 120, 160 mg/kg. The pattern of intoxication was similar in case of compared drugs and manifested in hypodynamia, impaired movement coordination, hind limbs paresis, though the manifestation degreethereof was more expressed in the groups with the introduction of DOC than in the case of the introduction of PLGA-DOC-FAD. It wasdetected that the LD50 for PLGA-DOC-FAD is 140 mg/kg, and for the DOC substance – 112 mg/kg. In case of subchronic administration, the detected toxic properties of drug depend on the size of the dose applied. The administration of a single dose of 22 mg/kg of PLGA-DOC-FAD caused lethal effects (2/10), reversible delay in weight gain and leucopenia in surviving animals, and an increase in the relativemass of the spleen. The use of PLGA-DOC-FAD in a single dose of 11 mg/kg didn’t cause death, was well tolerated and characterizedby similar toxicity with the docetaxel substance. <bold>Conclusion </bold>Based on experimental data, the toxic dose levels of PLGA-DOC-FAD were determined under acute and subchronic administration. The results obtained allowed us to recommend PLGA-DOC-FAD for further examination.</italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Введение </italic></bold><italic>Использование субмикронных векторизованных систем доставки, которые способствуют повышению избирательности действия и уменьшению побочного токсического влияния химиотерапии, – один из перспективных подходов к созданиюпротивоопухолевых химиопрепаратов. Разработана система доставки доцетаксела (ДОЦ) в составе полилактидгликолидных частиц (poly(lactic-co-glycolic acid), PLGA), модифицированных додециламидом фолиевой кислоты (ДФК) (частицы PLGA-ДОЦ-ДФК). <bold>Цель исследования </bold>– сравнительное токсикологическое исследование ДОЦ в форме частиц и в стандартной форме в остроми субхроническом экспериментах на мышах при внутривенном введении. <bold>Материалы и методы </bold>Исследование проведено на мышах-самках линии C57BL/6. При изучении острой токсичности препараты вводили в диапазоне доз 20, 60, 90, 120, 160 мг/кг. На протяжении 30 дней оценивали летальность, определялимассу тела, проводили патоморфологические исследования. Для изучения токсичности в условиях субхронического эксперимента препараты вводили ежедневно в течение 3 дней в разовых дозах 11 и 22 мг/кг и далее в течение 30 дней проводилинеобходимые исследования. <bold>Результаты </bold>При 1-кратном введении PLGA-ДОЦ-ДФК в дозах 20, 60, 90 мг/кг гибели животных не наблюдалось; в дозах120 и 160 мг/кг выявлена гибель животных на 1–4-е сутки. В случае применения субстанции ДОЦ гибель животных наступала в течение суток после введения доз 60, 90, 120, 160 мг/кг. Картина интоксикации была сходной для сравниваемыхпрепаратов и проявлялась в гиподинамии, нарушении координации движений, парезе задних конечностей, но степень их проявления была более выраженной в группах с введением ДОЦ, чем в случае введения PLGA-ДОЦ-ДФК. Было установлено, чтосредняя летальная доза (ЛД50) для PLGA-ДОЦ-ДФК составляет 140 мг/кг, а для субстанции ДОЦ – 112 мг/кг. При субхроническом введении выявленные токсические свойства препаратов зависят от величины примененной дозы. ВведениеPLGA-ДОЦ-ДФК в разовой дозе 22 мг/кг вызывало летальные эффекты (2/10), обратимую задержку прироста массыи лейкопению у выживших животных, увеличение относительной массы селезенки. Применение PLGA-ДОЦ-ДФК в разовойдозе 11 мг/кг гибели не вызывало, хорошо переносилось и характеризовалось сходной токсичностью с субстанцией ДОЦ. <bold>Заключение </bold>На основании экспериментальных данных определены уровни токсических доз PLGA-ДОЦ-ДФК при остроми субхроническом введении. Полученные результаты позволили рекомендовать препарат для дальнейшего изучения.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>docetaxel</kwd><kwd>folate-modified polymer particles</kwd><kwd>toxicity</kwd><kwd>mice</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>доцетаксел</kwd><kwd>фолатмодифицированные полимерные частицы</kwd><kwd>токсичность</kwd><kwd>мыши</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was supported by the Scientific Program of the NRC “Kurchatov institute” and Agreement No 14.607.21.0198 (RFMEFI60717X0198) of Ministry of Science and Higher Education of the Russian Federation.</funding-statement><funding-statement xml:lang="ru">Исследование проведено в рамках Программы деятельности НИЦ «Курчатовский институт» и Соглашения № 14.607.21.0198 (RFMEFI60717X0198) с Министерством науки и высшего образования Российской Федерации.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Prabhu R.H., Patravale V.B., Joshi M.D. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine 2015;10:1001–18. DOI: 10.2147/IJN.S56932.</mixed-citation><mixed-citation xml:lang="ru">Prabhu R.H., Patravale V.B., Joshi M.D. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomedicine 2015;10:1001–18. DOI: 10.2147/IJN.S56932.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Doppalapudi S., Jain A., Domb A.J., Khan W. Biodegradable polymers for targeted delivery of anti-cancer drugs. Expert Opin Drug Deliv 2016;13(6):891–909. DOI: 10.1517/17425247.2016.1156671.</mixed-citation><mixed-citation xml:lang="ru">Doppalapudi S., Jain A., Domb A.J., Khan W. Biodegradable polymers for targeted delivery of anti-cancer drugs. Expert Opin Drug Deliv 2016;13(6):891–909. DOI: 10.1517/17425247.2016.1156671.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Bahrami B., Mohammadnia-Afrouzi M., Bakhshaei P. et al. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumour Biol 2015;36(8):5727–42. DOI: 10.1007/s13277-015-3706-6.</mixed-citation><mixed-citation xml:lang="ru">Bahrami B., Mohammadnia-Afrouzi M., Bakhshaei P. et al. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumour Biol 2015;36(8):5727–42. DOI: 10.1007/s13277-015-3706-6.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Санжаков М.А., Игнатов Д.В., Прозоровский В.Н. и др. Синтез адресного конъюгата для фосфолипидной системы транспорта лекарств. Биомедицинская химия 2014;60(6): 713–6. DOI: 10.18097/pbmc20146006713. [Sanzhakov M.A., Ignatov D.V., Prozorovskiy V.N. et al. Development of Targeted Drug Delivery System: Synthesis of Conjugates of Address Fragment (RA-COOH) With Ligand (R-NH2). Biomeditsinskaya khimiya = Biomedical chemistry 2014;60(6):713–6. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Санжаков М.А., Игнатов Д.В., Прозоровский В.Н. и др. Синтез адресного конъюгата для фосфолипидной системы транспорта лекарств. Биомедицинская химия 2014;60(6): 713–6. DOI: 10.18097/pbmc20146006713. [Sanzhakov M.A., Ignatov D.V., Prozorovskiy V.N. et al. Development of Targeted Drug Delivery System: Synthesis of Conjugates of Address Fragment (RA-COOH) With Ligand (R-NH2). Biomeditsinskaya khimiya = Biomedical chemistry 2014;60(6):713–6. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Suvorov N.V., Mironov A.F., Grin M.A. Folic acid and its derivatives for targeted photodynamic therapy of cancer. Rus Chem Bulletin 2017;66(11):1982–2008. DOI: 10.1007/s11172-017-1973-7.</mixed-citation><mixed-citation xml:lang="ru">Suvorov N.V., Mironov A.F., Grin M.A. Folic acid and its derivatives for targeted photodynamic therapy of cancer. Rus Chem Bulletin 2017;66(11):1982–2008. DOI: 10.1007/s11172-017-1973-7.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Montero A., Fossella F., Hortobagyi G., Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6(4):229–39. DOI: 10.1016/S1470-2045(05)70094-2.</mixed-citation><mixed-citation xml:lang="ru">Montero A., Fossella F., Hortobagyi G., Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6(4):229–39. DOI: 10.1016/S1470-2045(05)70094-2.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. PRODUCT MONOGRAPH TAXOTERE® (docetaxel for injection). Sanofi-Aventis Canada Inc. Laval (Québec), 2017. Available by: URL: https://www.products.sanofi.ca/en/taxotere.pdf.</mixed-citation><mixed-citation xml:lang="ru">PRODUCT MONOGRAPH TAXOTERE® (docetaxel for injection). Sanofi-Aventis Canada Inc. Laval (Québec), 2017. Available by: URL: https://www.products.sanofi.ca/en/taxotere.pdf.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Su C.Y., Liu J.J., Ho Y.S. et al. Development and characterization of docetaxel-loaded lecithin-stabilized micellar drug delivery system (LsbMDDs) for improving the therapeutic efficacy and reducing systemic toxicity. Eur J Pharm Biopharm 2018;123:9–19. DOI: 10.1016/j.ejpb.2017.11.006.</mixed-citation><mixed-citation xml:lang="ru">Su C.Y., Liu J.J., Ho Y.S. et al. Development and characterization of docetaxel-loaded lecithin-stabilized micellar drug delivery system (LsbMDDs) for improving the therapeutic efficacy and reducing systemic toxicity. Eur J Pharm Biopharm 2018;123:9–19. DOI: 10.1016/j.ejpb.2017.11.006.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Nikolskaya E.D., Zhunina O.A., Yabbarov N.G. et al. The docetaxel polymeric form and its antitumor activity. Russian J Bioorganic Chem 2017;43:278–85. DOI: 10.1134/S1068162017030116.</mixed-citation><mixed-citation xml:lang="ru">Nikolskaya E.D., Zhunina O.A., Yabbarov N.G. et al. The docetaxel polymeric form and its antitumor activity. Russian J Bioorganic Chem 2017;43:278–85. DOI: 10.1134/S1068162017030116.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Hu L., Pang S., Hu Q. et al. Enhanced antitumor efficacy of folate targeted nanoparticles co-loaded with docetaxel and curcumin. Biomed Pharmacother 2015;75:26–32. DOI: 10.1016/j.biopha.2015.08.036.</mixed-citation><mixed-citation xml:lang="ru">Hu L., Pang S., Hu Q. et al. Enhanced antitumor efficacy of folate targeted nanoparticles co-loaded with docetaxel and curcumin. Biomed Pharmacother 2015;75:26–32. DOI: 10.1016/j.biopha.2015.08.036.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Esmaeili F., Ghahremani M.H., Ostad S.N. et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target 2008;16(5):415–23. DOI: 10.1080/10611860802088630.</mixed-citation><mixed-citation xml:lang="ru">Esmaeili F., Ghahremani M.H., Ostad S.N. et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target 2008;16(5):415–23. DOI: 10.1080/10611860802088630.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Poltavets Y.I., Zhirnik A.S., Zavarzina V.V. et al. In vitro anticancer activity of folate-modifed docetaxel-loaded PLGA nanoparticles against drug-sensitive and multidrug-resistant cancer cells. Cancer Nanotechnology 2019;10(2). DOI: 10.1186/s12645-019-0048-x.</mixed-citation><mixed-citation xml:lang="ru">Poltavets Y.I., Zhirnik A.S., Zavarzina V.V. et al. In vitro anticancer activity of folate-modifed docetaxel-loaded PLGA nanoparticles against drug-sensitive and multidrug-resistant cancer cells. Cancer Nanotechnology 2019;10(2). DOI: 10.1186/s12645-019-0048-x.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Полтавец Ю.И., Воронцов Е.А., Заварзина В.В. и др. Полимерный комплекс для молекулярно-прицельной терапии и способ его получения. Патент РФ № 2 675 810 C1 от 19.12.2017. [Poltavets Yu.I., Vorontsov E.A., Zavarzina V.V. et al. Polymeric complex for molecular targeted therapy and method for its obtaining. RU 2 675 810 C1, 19.12.2017. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Полтавец Ю.И., Воронцов Е.А., Заварзина В.В. и др. Полимерный комплекс для молекулярно-прицельной терапии и способ его получения. Патент РФ № 2 675 810 C1 от 19.12.2017. [Poltavets Yu.I., Vorontsov E.A., Zavarzina V.V. et al. Polymeric complex for molecular targeted therapy and method for its obtaining. RU 2 675 810 C1, 19.12.2017. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Council of Europe. European Convention for the protection of vertebrate animals used for experimental and other scientific purposes. ETS 1986;123.</mixed-citation><mixed-citation xml:lang="ru">Council of Europe. European Convention for the protection of vertebrate animals used for experimental and other scientific purposes. ETS 1986;123.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Gaoe H., Pang Z., Pan S. et al. Antiglioma effect and safety of docetaxelloaded nanoemulsion. Arch Pharm Res 2012;35(2):333–41. DOI: 10.1007/s12272-012-0214-8.</mixed-citation><mixed-citation xml:lang="ru">Gaoe H., Pang Z., Pan S. et al. Antiglioma effect and safety of docetaxelloaded nanoemulsion. Arch Pharm Res 2012;35(2):333–41. DOI: 10.1007/s12272-012-0214-8.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Bissery M.C., Guénard D., Guéritte-Voegelein F., Lavelle F. Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue. Cancer Res 1991;51(18):4845–52.</mixed-citation><mixed-citation xml:lang="ru">Bissery M.C., Guénard D., Guéritte-Voegelein F., Lavelle F. Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue. Cancer Res 1991;51(18):4845–52.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Беленький М.Л. Элементы количественной оценки фармакологического эффекта. Л.: Государственное издательство медицинской литературы (Медгиз), 1963. С. 81–106. [Belen’kij M.L. Elements of quantitative assessment of pharmacological effect. Leningrad: State Publishing House of Medical Literature (Medgiz) 1963. P. 81–106. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Беленький М.Л. Элементы количественной оценки фармакологического эффекта. Л.: Государственное издательство медицинской литературы (Медгиз), 1963. С. 81–106. [Belen’kij M.L. Elements of quantitative assessment of pharmacological effect. Leningrad: State Publishing House of Medical Literature (Medgiz) 1963. P. 81–106. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Sun Y., Zhao Y., Teng S. et al. Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy. Int J Nanomedicine 2018;14:135–48. DOI: 10.2147/IJN.S181296.</mixed-citation><mixed-citation xml:lang="ru">Sun Y., Zhao Y., Teng S. et al. Folic acid receptor-targeted human serum albumin nanoparticle formulation of cabazitaxel for tumor therapy. Int J Nanomedicine 2018;14:135–48. DOI: 10.2147/IJN.S181296.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Lv W., Cheng L., Li B. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer. Chem Pharm Bull 2015;63(2):68–74. DOI: 10.1248/cpb.c14-00423.</mixed-citation><mixed-citation xml:lang="ru">Lv W., Cheng L., Li B. Development and evaluation of a novel TPGS-mediated paclitaxel-loaded PLGA-mPEG nanoparticle for the treatment of ovarian cancer. Chem Pharm Bull 2015;63(2):68–74. DOI: 10.1248/cpb.c14-00423.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Demoy M., Andreux J.P., Weingarten C. et al. Spleen capture of nanoparticles: influence of animal species and surface characteristics. Pharm Res 1999;16(1):37–41. DOI: 10.1023/A:1018858409737.</mixed-citation><mixed-citation xml:lang="ru">Demoy M., Andreux J.P., Weingarten C. et al. Spleen capture of nanoparticles: influence of animal species and surface characteristics. Pharm Res 1999;16(1):37–41. DOI: 10.1023/A:1018858409737.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Трещалин И.Д., Переверзева Э.Р., Бодягин Д.А. и др. Сравнительное экспериментальное токсикологическое исследование доксорубицина и его наносомальных лекарственных форм. Российский биотерапевтический журнал 2008;7(3):24–33. [Treshсhalin I.D., Pereverzeva E.R., Bodyagin D.A. et al. Comparative experimental toxicological study of doxorubicin and nanoparticle formulations. Rossiyskiy bioterapevticheskiy zhurnal = Russian Jornal of Biotherapy 2008;7(3):24–33. (In Russ.)].</mixed-citation><mixed-citation xml:lang="ru">Трещалин И.Д., Переверзева Э.Р., Бодягин Д.А. и др. Сравнительное экспериментальное токсикологическое исследование доксорубицина и его наносомальных лекарственных форм. Российский биотерапевтический журнал 2008;7(3):24–33. [Treshсhalin I.D., Pereverzeva E.R., Bodyagin D.A. et al. Comparative experimental toxicological study of doxorubicin and nanoparticle formulations. Rossiyskiy bioterapevticheskiy zhurnal = Russian Jornal of Biotherapy 2008;7(3):24–33. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Peracchia M.T., Fattal E., Desmaële D. et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 1999;60(1):121–8. DOI: 10.1016/S0168-3659(99)00063-2.</mixed-citation><mixed-citation xml:lang="ru">Peracchia M.T., Fattal E., Desmaële D. et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 1999;60(1):121–8. DOI: 10.1016/S0168-3659(99)00063-2.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
